Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Gilead and Galapagos's conscious uncoupling
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
ASH 2024 movers – moments of reckoning for menin and BTK
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
ASH 2024 – Galapagos turns Car-T manufacturing on its head
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
ASH 2024 – Miltenyi throws its hat into the fast-Car ring
And the company might one day follow Galapagos into decentralised manufacturing.
ASH 2024 preview – CD19 back on the agenda
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
